(十七)列伐沙班(rivaroxaban/Xarelto)Bayer公司开发,2008年9月和10月分别获得加拿大卫生部和欧盟委员会的批准,用于预防经历选择性全髋或全膝置换术患者的静脉血栓栓塞事件。列伐沙班为一日1次口服用片剂,它属直接 (17) Developed by Bayer, rivaroxaban / Xarelto, approved by the Health Canada and the European Commission in September and October 2008 respectively for the prevention of patients undergoing selective total hip or total knee replacement Venous thromboembolic events. Rivaroxaban is administered orally once a day as a tablet, which is straightforward